Transforming the measurement of modified proteins using mass spectrometry data and advanced software

** 摘要 ** 这是由InnovateUK赠款资助的项目部分，运行时间超过9个月。目标是提高Turbinia软件分析蛋白质修饰形式的能力。这是Turbinia无法单独使用软件解决的问题，因此我们将与罗伊斯研究所的质谱专家合作。Turbinia做什么，它如何帮助我们的客户 **Turbinia正在开发一个新的软件平台，以帮助制药和诊断行业的客户开发更多更好的药物和测试。药物发现过程可以被认为是一个销售过程。你找到线索，过滤掉那些不好的，直到你只剩下那些真正有潜力的，然后继续努力，直到你完成销售。Turbinia的软件可以帮助寻找可能的新药和诊断方法的线索，这些线索在传统上很难找到，并有助于确保传递到下一阶段的线索可能会产生结果。我们的“领先发现”市场被称为蛋白质组学。**创新解决的需求或挑战 ** 2021年，全球制药市场在研发方面的支出为2980亿美元，但FDA仅批准了50种新药，而20世纪70年代每年批准的新药超过150种。我们相信，该项目将使我们能够为药物发现过程提供更多的候选生物标志物。罗伊斯研究所将如何提供帮助 ** 首先，他们在这个高度专业化的领域的专业知识。第二，通过提供专门设计的测试样品（以及来自它们的数据），使Turbinia能够理解和解决蛋白质修饰形式所带来的分析问题。最后，通过提供使用当前标准技术运行的比较分析和盲法试验来衡量我们的进展。Turbinia项目成果 ** 软件的第一个版本已准备好向客户演示。通过原型开发和Royce测试的迭代循环进行磨练。**进入市场的途径 ** 软件销售将在全球范围内直接进行，并通过跨国分销商进行-这是该团队在该领域非常熟悉的模式。**更广泛的影响 ** 该产品将帮助客户开发新药。如果这个项目能够使Turbinia的英国客户将一种新药推向市场，那么销售给他们的价值可以以数十亿美元来衡量，同时挽救生命并减轻NHS的压力。

**Summary**This is a project part funded by an InnovateUK grant, running over 9 months. The goal is to improve the ability of Turbinia's software to analyse modified forms of proteins. This is a problem Turbinia have been unable to solve with software alone, so we will be working with the mass spectrometry experts at the Royce Institute.**What Turbinia does, how it helps our customers**Turbinia is developing a new software platform to help customers in the pharmaceutical and diagnostic industries to develop more and better drugs and tests. The drug discovery process can be thought of like a sales process. You find leads, filter out the poor ones until you only have those with true potential, then work on those until you close the sale. Turbinia's software helps find leads for possible new drugs and diagnostics where it has traditionally been hard to find them and helps ensure that the leads passed on to the next stage are likely to yield results. Our "lead-finding" market is called proteomics.**Need or challenge addressed by your innovation**In 2021 the global pharmaceutical market spent $298b on R&D, and yet the FDA only approved 50 new drugs - compared to over 150 per year in the 1970s. We believe that this project will enable us to deliver more candidate biomarkers to the drug discovery process.**How the Royce Institute will help**Firstly, with their expertise in this highly specialised field. Secondly by providing test samples (and the data from them) specifically designed to enable Turbinia to understand and solve the analysis problems posed by modified forms of proteins. Finally, by providing comparative analyses run using the current standard techniques and a blinded trial to measure our progress.**Outcomes of the project for Turbinia**A first version of the software ready to demonstrate to customers. Honed from iterative loops of prototype development and testing with the Royce.**Routes to market**Software sales will be world-wide, direct and via multinational distributors - a model the team is very familiar with in this space.**Wider impacts**The product will help customers develop new drugs. If this project enables Turbinia's UK customers to bring just one new drug to market, the value in sales to them could be measured in billions, while saving lives and easing the pressure on the NHS.